Buy the full study
Summary
The global bioanalytical market has experienced dynamic growth, particularly since the outbreak of the COVID-19 pandemic in 2020, which created new growth opportunities due to increased risks and consumer focus on food and pharmaceutical products. The market, which encompasses the health, food and environmental sectors, is mainly driven by strict regulations and growing consumer demand for safe, healthy products.
Eurofins Scientific, a key player in this field, holds around 75% of the French bioanalytical market, with growth outstripping that of the overall market. In terms of figures, the value of the global market was estimated at around $2.4 billion and is expected to grow at a CAGR of 7.8% over the period 2018-2023, potentially reaching $4.8 billion in 2023. For France in particular, Eurofins Scientific's revenue data points to sustained growth, with sales reaching €1,089 million by 2020, suggesting that the total French market could be valued at around €1,452 million.
Analysis of demand in the French bioanalysis market
The bioanalytical market has seen remarkable growth in its main segments: environmental, food and pharmaceutical analyses, all of which are evolving rapidly in line with increased consumer and regulatory demands. In the environmental segment, strict regulations concerning pollutants and mandatory monitoring were the driving force, with companies operating in high-risk industries, public entities and health agencies contributing significantly to the increase in demand. Growth in this segment averaged 5.9% a year. In the food industry, growing consumer concern about food safety and scandals has led to a more vigilant approach to product composition.
With a sector value of around 125 billion euros, despite a slight drop in consumer spending on food products, considerable investments have been made to guarantee food quality. New regulations, such as the ban on certain pesticides and additives like titanium dioxide, further increase the demand for meticulous food analysis. In addition, food analysis is increasingly vital in view of growing preferences for specialized diets such as gluten-free and lactose-free products. In the pharmaceutical sector, safety and efficacy are at the heart of market demand. Clinical trials, safety testing and drug monitoring are an integral part of this sector, not least because of the production boom that has seen annual increases of between 3.8% and 5.9% in recent years. The weight of health scandals and counterfeiting problems has led to renewed vigilance and a need for more rigorous bioanalytical services, underlining the indispensable nature of bioanalysis in protecting public health.
on a global scale, bioanalysis dedicated to DNA testing and genomics, which represents just over a quarter of all bioanalytical activities, points to a total market of over 11 billion dollars by 2020.
It is clear from these observations that pressure for stringent regulations, combined with growing consumer awareness and the urgent need to verify the safety of consumables and pharmaceuticals, is driving overall demand across the dynamic bioanalytical market
Leading generalists in bioanalysis
The bioanalytical market in France boasts a number of outstanding names that dominate the sector thanks to their comprehensive services and extensive presence.
- Eurofins occupies a leading position, being recognized not only as a figurehead in the French market, but also as a global authority in the field. Building on its substantial market share, Eurofins continues to expand its footprint both nationally and internationally through strategic acquisitions that reinforce its expertise and range of services.
- Carso, strengthens the generalist segment with its solid portfolio of bioanalytical services. Carso has succeeded in carving out a strong market position by aligning its offerings with the evolving needs of the industries it serves, ranging from healthcare to food and environmental sectors.
- Mérieux NutriSciences, a company that consolidates the strong position of generalists in the market thanks to its extensive testing and analysis capabilities that meet a wide range of customer requirements.
Other operators
- SGS, Intertek and Bureau Veritas are notable participants in this field. Each of these companies contributes to the bioanalytical sector by focusing on particular niches in the three primary segments of environmental, food and pharmaceutical analysis, offering tailor-made solutions to their customers. Their enhanced roles ensure that the market remains dynamic and competitive, offering customers a wide range of options from hyper-specialized services to a more diversified palette of services.
These key players - generalists and followers - define the competitive landscape of the bioanalytical market in France. Together, they underpin the robustness of the market, drive innovation through research and development, and ensure that the demands of a health- and regulation-conscious consumer base are met with precision and professionalism. As the bioanalytical sector continues to adapt to the challenges of public health crises, environmental concerns and stringent regulations, the agility of these key players remains essential to the industry's continued vitality and progress.
to understand this market
Detailed content
Inforamtion
- Number of pages : 30 pages
- Format : Digital and PDF versions
- Last update : 20/10/2021
Summary and extracts
1 Market overview
1.1 Definition and scope of the study
Bioanalysis consists of analyze biomolecules to identify, quantify and characterize them in order to obtain marketing authorization for a product .
The origin of bioanalysis in pharmacy comes from the emergence in Europe of drugs manufactured with biotechnologies and corresponding to the label " Products produced by recombinant DNA techniques "of the European Pharmacopoeia. The methods of analysis of biomolecules are clearly different from those of the classical analysis of relatively small organic compounds. This has given rise to a new branch of analysis: bioanalysis.
The bioanalysis market affects three sectors: health, agri-food and the environment . In reality, this is analytical subcontracting for pharmaceutical laboratories, cosmetics manufacturers, food companies, etc.
This market is seen as a rather dynamic market and while its CAGR over the period 2012-2019 was in double digits, this remained positive despite the health crisis. Since 2020, the Covid-19 crisis offers precisely new growth prospects for this market due to increased risk, consumer distrust of their food and pharmaceutical products that is constantly increasing
This dynamism is mainly based on a limited number of companies that are leaders in their field: Eurofins Scientific is even the world leader in the sector. Eurofins Scientific, as well as other companies such as Phytocontrol and Carso, continue to expand internationally through new laboratories and external growth operations aimed at strengthening the expertise already possessed by these companies or, on the contrary, helping them to develop a more complete and differentiated offer
1.2 A very promising global market
According to a **** study by the Eurofins bioanalytical group, the global bioanalytical market is a market and very promising, particularly in the food sector . Eurofins estimated at the time that the global market could reach €*.* billion in value in ****.
More recent figures estimate the global bioanalytical market at US$*.* billion in ...
1.3 Sustained growth in the French market
The French market has witnessed a sustained increase between **** and **** (***) as shown in the following graph. This increase accelerated further from **** when the Covid-** crisis boosted the activities of bioanalytical laboratories mainly in the food and pharmaceutical segments
Eurofins Scientific Sales France, ****-****, million euros Source: ****
We see that Eurofins Scientific's ...
1.4 Overview: PESTEL analysis
In order to understand the environment of the bioanalysis market in France, its drivers and structural restraints, a PESTEL analysis is proposed to determine the impact of various factors on the market.
1.5 The health crisis as a partial redefinition of the market
The bioanalytical sector is holding up rather well in the face of the health crisis, mainly thanks to the robustness of the food and pharmaceutical industries, both of which are considered essential. However, there is some uncertainty for **** and **** regarding the growth of the sector: while it averaged *% between **** and **** (***), it ...
2 Analysis of the demand
2.1 Good demand in all three market segments
Demand is strong in the three main segments of the bioanalytical market, namely environmental, food and pharmaceutical analysis.
Environmental analysis
Among the main clients of bioanalytical laboratories in the environmental sector are companies (***).
One of the main factors driving demand in this segment of bioanalysis is the changing regulatory environment, e.g., ...
2.2 Traceability and transparency are becoming essential in the food industry
According to a Challenges survey, **.*% of French people now consider that the safety of products bought in supermarkets is declining. This is particularly linked to the numerous scandals that have broken out in the food industry and is pushing consumers to be more vigilant about the quality and traceability of the ...
2.3 The credibility of the pharmaceutical market is at risk
The rise of counterfeiting in the pharmaceutical industry
Globalization, market deregulation and the free movement of certain goods are leading to the wider distribution of counterfeit products.
According to a study conducted for Leem (***), there has been a growing mistrust among French people that has affected all types of medicines in ...
3 Market structure
3.1 The different types of actors
Segmentation *: three categories of companies
There are three main types of players in the bioanalysis market in France: [***]
From pure players generalists The three largest are Eurofins, Carso and Mérieux NutriSciences. Eurofins has a significant market share in the healthcare segment. From follower" operators and diversified, generally specializing in one ...
3.2 The different growth strategies
Concentration
Bioanalytical laboratories are seeking to increase their volumes in order to reach a significant size and consequently reduce the cost of analysis, gains that are notably passed on to clients. For example, Eurofins doubled its size over the period ****-**** thanks to an acquisition volume of between €** and €*** million per ...
3.3 A market marked by the external growth strategy
The bioanalysis market is responding to the need to reduce costs through economies of scale, so it seems logical that the largest players in the market are looking to make acquisitions one of the major levers of their growth.
4 Analysis of the offer
4.1 The main market segments and their offer
There are three main areas of expertise in the bioanalysis sector in France: the environment, agri-food and health.
Bioanalysis in the environment
Bioanalysis in the environmental sector is concerned with various components of the environment, including air quality, water quality, solids analysis and building quality
Environmental analysis holds **% to **% of the ...
4.2 Prices for analysis services
An overall decrease in prices
There has been an overall decline in prices over the last ** years, which has been made possible by productivity gains via of investments in R
For example, some laboratories can now carry out a toxin test in two days, at a cost of between €*** and €***, compared ...
4.3 Major market trends
The slight slowdown in the market compared to **** can be explained in several ways. Growth was partly driven by outsourcing of certain services, but this trend is slowing down, directly influencing the growth of the bioanalytical market.
In addition, investments in R
The development of the organic sector in the food ...
5 Regulation
5.1 NAF Code
The following NAF (***) code was used to compile statistics for the bioanalysis market in France: [***]
Class **.**: Technical testing and analysis activities
It should be noted that this NAF code also includes technical inspection of buildings and machinery as well as vehicle inspection.
6 Positioning of the actors
6.1 Segmentation
Among the main players in the bioanalysis market, there are three main generalist leaders (***), which together account for almost **% of total market sales, and a number of follow-on operators, the main ones being SGS, Intertek and Bureau Veritas.
M€: billions of euros m€: millions of euros
- Eurofins
- Carso groupe
- Mérieux NutriSciences
- SGS
- Intertek
- Bureau Veritas BV
- Phytocontrol
- Qualtech (IFBM Groupe)
- Valbiotis
- Abbott Groupe
- Agilent Technologies
- Beckman Coulter
- Bio-Rad Laboratories
- Genomic Vision
- LFB Groupe
- Novacyt
- Qiagen
- Randox Laboratories
- Roche Diagnostics France (Roche Group)
- Thermo Fisher Diagnostics
List of charts
- Bioanalytical market size and forecast
- Eurofins Scientific Sales
- Production of the pharmaceutical industry
- Poll: "In recent years, would you say that the safety of products bought in supermarkets is rather in...?"
- Impact of food scandals on consumer habits
All our studies are available online in PDF format
Take a look at an example of our research on another market!
Latest news
Val-d'Oise: Bureau Veritas invests and relocates its laboratory - 22/11/2023
- Bureau Veritas in Saint-Ouen-l'Aumône for over 30 years
- The subsidiary employs 120 people
- The Bureau Veritas group employs 82,000 people worldwide, including 8,000 in France
- Bureau Veritas Group sales of 5.6 billion euros
Biomedicaments : LFB Biomanufacturing doubles its production capacity in Alès - 06/10/2023
- LFB Biomanufacturing has announced a €20 million investment in Alès, in the Gard region of France.
- LFB Biomanufacturing produces a recombinant drug from rabbit milk protein. 50% of pharmaceutical products under development are biomedicines.
- LFB Biomanufacturing has two 1,000-liter bioreactors. They plan to acquire six 2,000-liter single-use bioreactors, including two as part of this investment.
- The company plans to recruit 50 new employees by 2026, bringing its total workforce to 125.
- The LFB Biomanufacturing site, established 27 years ago, is approved by the US Food and Drug Administration.
- The LFB group, based in Les Ulis (Essonne), has sales of 524 million euros in 2022 and employs 2,600 people.
- A plant under construction in Arras (Pas-de-Calais).
Valbiotis clinically validates the first anti-diabetic dietary supplement - 17/09/2023
- Valbiotis has been developing a natural plant-based product for type 2 diabetes called Totum.63 for ten years.
- The company was founded in La Rochelle in 2014.
- Diabetes affects 537 million people worldwide, with 900 million pre-diabetics (International Diabetes Federation estimates in 2021).
- Valbiotis has invested €50 million in R&D to develop Totum.63.
- In 2020, the company signed a worldwide licensing agreement with Nestlé Health Science (NHS).
- NHS is to pay Valbiotis a lump sum of 4 million euros, bringing total payments to 7.5 million out of a potential 66 million, depending on commercial performance.
- The company is completing its study and preparing to launch its product in 2024.
- The company employs 50 people
Thermo Fisher solid despite a more difficult environment - 23/06/2023
- Thermo Fisher Scientific sales in 2022: $44.9 billion
- Thermo Fisher sales by business segment: analytical technologies (15%), specialized diagnostic products (11%), life sciences solutions (30%), laboratory products and services including CRO services (50%)
Abbott: improvement and investment - 20/06/2023
- Abbott generates around 60% of its sales outside the United States
- The company achieved sales of $43.6 billion in 2022
- The company acquired St. Jude Medical in 2017 for $25 billion
Thermo Fisher expands capacity at Bourgoin-Jallieu - 20/04/2023
- Thermo Fisher Scientific plant in Bourgoin-Jallieu, Isère.
- The site employs nearly 600 people.
- Thermo Fisher Scientific sales in 2022: $44.92 billion (around €41 billion).
- The group employs 2,800 people in France, on 9 sites.
Companies quoted in this study
This study contains a complete overview of the companies in the market, with the latest figures and news for each company. :
Choosing this study means :
Access to more than 35 hours of work
Our studies are the result of over 35 hours of research and analysis. Using our studies allows you to devote more time and added value to your projects.
Benefit from 6 years' experience and over 1,500 industry reports already produced
Our expertise enables us to produce comprehensive studies in all sectors, including niche and emerging markets.
Our know-how and methodology enable us to produce reports that offer unique value for money.
Access to several thousand articles and paid-for data
Businesscoot has access to all the paid economic press as well as exclusive databases to carry out its market research (over 30,000 articles and private sources).
To enhance our research, our analysts also use web indicators (semrush, trends, etc.) to identify market trends and company strategies. (Consult our paying sources)
Guaranteed support after your purchase
A team dedicated to after-sales service, to guarantee you a high level of satisfaction. +44 238 097 0676
A digital format designed for our users
Not only do you have access to a PDF, but also to a digital version designed for our customers. This version gives you access to sources, data in Excel format and graphics. The content of the study can therefore be easily retrieved and adapted for your specific needs.
Our offers :
the bioanalysis market | France
- What are the figures on the size and growth of the market?
- What is driving the growth of the market and its evolution?
- What is the positioning of companies in the value chain?
- Data from several dozen databases
Pack 5 études (-15%) France
- 5 études au prix de 75,6€HT par étude à choisir parmi nos 800 titres sur le catalogue France pendant 12 mois
- Conservez -15% sur les études supplémentaires achetées
- Choisissez le remboursement des crédits non consommés au terme des 12 mois (durée du pack)
Consultez les conditions du pack et de remboursement des crédits non consommés.
Our customer references
They have consulted our studies
Discover the opinions (+500)
Malcolm Vincent
Astoria Finance
Gregoire de Castelnau
Stags Participations
Timothé Huignard
PWC
Paul-Alexis Kebabtchieff
BCG
Aymeric Granet
Publicis Consultant
interviews & case studies
All interviews and case studies (45)
